Oxaloacetate May Help Breast Cancer Survivors With Cognitive Symptoms
In a small single-arm study, breast cancer survivors with cancer-related cognitive impairment received the supplement oxaloacetate for eight weeks. All 16 evaluable participants showed clinically meaningful cognitive improvement, and fatigue and physical function also improved, with gastrointestinal side effects being the main tolerability issue. A randomized placebo-controlled trial is planned to confirm the findings.
Oxaloacetate is a naturally occurring metabolite tied to cellular energy production and glutamate regulation, a neurotransmitter linked to cognition. In the single-arm trial, 16 evaluable breast cancer survivors took the supplement for eight weeks; their average cognitive score nearly doubled, and fatigue and physical function also improved, with insomnia showing a favorable trend.
Cancer-related cognitive impairment—often called chemo brain or brain fog—is common among breast cancer survivors and can affect people with other cancers too. Its causes remain uncertain, though it became more prominent after adjuvant chemotherapy, and some regimens include agents that cross the blood-brain barrier and can harm neurons. Gastrointestinal effects were the main tolerability concern.
If confirmed, an easily used supplement could offer a low-burden option for breast cancer survivors coping with cognitive symptoms, potentially easing difficulties with work, daily tasks, and social participation. Because the current evidence is small and uncontrolled, patients and clinicians may view it cautiously until randomized results arrive. Broader uptake could also raise questions about cost, supplement quality, and access, while drawing more attention to cognitive rehabilitation and survivorship care.